Research Funded by Box Rallies

Featured Research

Professor Pitson and his team are tackling one of the most aggressive blood cancers — acute myeloid leukaemia (AML) — where survival rates can be as low as 10%.

Explore Research

A new approach to boosting resistance to fungal infection in cancer patients

A new targeted therapy for resistant HER2+ breast cancers

A new therapeutic opportunity for gastrointestinal cancers

A patient-derived discovery platform for companion biomarker development in prostate cancer

A targeted therapy to enhance treatment efficacy and neuroprotection in glioblastoma

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia

Advancing CAR-T cell therapy for extracranial solid paediatric cancers

Advancing Liquid Biopsy Testing: Harnessing Epigenetics for Early Detection of Residual and Recurrent Breast Cancer

Advancing Telomerase Inhibitors as potential cancer therapeutics

CAPP3: a randomized dose finding non inferiority study of aspirin to prevent cancer in Lynch Syndrome

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors

Defining the cellular determinants that drive dynamin inhibitor induced cell death and in vivo efficacy against glioblastoma

Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management

Defining the critical role of osteoclasts in multiple myeloma cell growth and activation in bone

Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer

Developing a new blood-based screening test for bowel cancer

Developing a novel targeted therapy for treating chemotherapy-resistant leukaemia

Developing inhibitors of the LMO4 oncoprotein